HIV Drug Development--Emerging Technologies (Technical Insights)

 

Regular Price: USD 4,950

Special Price USD 3,465

30% OFF

* Required Fields

Regular Price: USD 4,950

Special Price USD 3,465

PAY BY INVOICE

Be the first to review this product

This research service discusses technology developments in the HIV drugs sector.

Table of Contents

HIV Drug Development--Emerging Technologies (Technical Insights), Executive SummaryIntroductionIntroduction to HIVPrevalenceScope and MethodologyScopeMethodologyHIV Drug Development--Emerging Technologies (Technical Insights), Technology and Applications View PointTechnology PrimerDrugsVaccinesMicrobicidesThe Red Ribbon ProjectTrends and Important Clinical TrialsIn DevelopmentGlobal ScenarioImportant Clinical TrialsHIV Drug Development--Emerging Technologies (Technical Insights), Technology Adoption Factor AnalysisDrivers and ChallengesDriversChallengesRegulatory Hurdles and FundingRegulatory HurdlesFundingHIV Drug Development--Emerging Technologies (Technical Insights), Technological Advancements--DrugsTechnological Advancements--CompaniesViral Entry Inhibitor-Based Monoclonal Antibody for HIV Treatment--USANovel Entry Inhibitor-Based Drug for Protecting Healthy Cells from HIV Infection--CanadaInnovative Entry Inhibitor-Based Drug Pipeline as HIV Therapeutics--USANucleoside Reverse Transcriptase Inhibitor Drug-Based Therapy for Prevention of HIV Infection--USADrug Preventing the Action of Enzyme Required for Replication--USAEntry Inhibitor-Based Drug for Prevention of HIV Infection--USAReverse Transcriptase Enzyme Inhibitor for Prevention of Fresh Infection of Cells--USATelomerase-Based Drug for Enhancing Antiviral Activity Targeting HIV Infection--ChinaTechnological Advancements--Research InstitutionsDynamic Host-Viral Interactions to Aid in Drug DevelopmentScientists Reveal the Molecule Involved in HIV Integration with Host Genetic ComponentHIV Drug Development--Emerging Technologies (Technical Insights), Technological Advancements--Vaccines and MicrobicidesTechnological Advancements in Companies--VaccinesAdVac-Based Vaccines to Tackle HIV--NetherlandsDNA-Based Vaccine for HIV--U.S.Monoclonals for Blocking HIV--U.S.Plant-Based HIV vaccines--U.S.Therapore Technology-Based HIV Vaccine--U.S.Dendritic Cell Technology for AIDS Vaccine--United KingdomTechnological Advanvements in Companies--MictrobicidesGel Based Microbicide for the Prevention of HIV Infection--CanadaMicrobicide Based Gel Tackling HIV Infection--AustraliaMicrobicide-Based Gel for Counter-Attacking HIV Infection--U.S.Oligonucleotide-Based Microbicide for HIV Prevention--U.S.Pyrimidinedione Series of Compounds as Topical Microbicide--South Korea/U.S.Research InstitutionsVaccine to Tackle HIV Using Genetically Modified Tobacco--UK Retroviral-Based Approach for Interfering with HIV Replication--IndiaLiposome-Based Adjuvant for Development of Vaccines--IndiaAdenovector-Based Vaccine to Target HIV--U.S.Novel Targets for Antiviral Approach against HIV--IndiaPlant-Based Vaccine for HIV--RussiaHIV Drug Development--Emerging Technologies (Technical Insights), Key Patents; Contacts; and GlossaryKey PatentsPatents--Drugs and DevelopmentsPatents--VaccinesContacts and GlossaryContactsGlossaryHIV Drug Development--Emerging Technologies (Technical Insights), Frost & Sullivan 2006 Science & Technology AwardsTechnology Innovation AwardAward DescriptionAward RecipientExcellence in Technology AwardAward Description.Award RecipientExcellence in Research AwardAward DescriptionAward RecipientHIV Drug Development--Emerging Technologies (Technical Insights), Decision Support DatabaseDatabase TablesNumber of Biotech Companies (1999-2006)Government Investment in Biotech R&D (1999-2006) Private Investment in Biotech (1999-2006)HIV Prevalence (1999-2006)AIDS Mortality (1999-2006)




Related Research

Release Date : 08-Sep-17

Region : Global

Release Date : 08-Sep-17

Region : Global

Release Date : 01-Sep-17

Region : Global

Release Date : 25-Aug-17

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.